Le Lézard
Classified in: Health
Subjects: PDT, FEA

The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application


STOCKHOLM, Dec. 23, 2021 /PRNewswire/ -- The Medical Products Agency in Sweden has agreed to be reference member state for Moberg Pharma AB's registration application for MOB-015 (nail fungus treatment). The company will submit the registration application in Europe through the decentralized process, and market approval is expected in 2023.

Moberg Pharma will submit a full application, which offers the possibility of data exclusivity in Europe for up to 10 years following market approval. Moberg Pharma has been ready to submit the registration application as soon as the authority can receive it. Due to limited resources and many parallel ongoing applications, the Swedish Medical Products Agency has now announced that the application can be submitted in March 2022. The company's goal remains unchanged, to receive its first market approval and launch MOB-015 in 2023.

"We are advancing toward the company's goal to register a new and improved nail fungus drug. The need for a treatment alternative that can truly cure the nail infection is great, which means that MOB-015 can achieve a unique position through its high antifungal effect," says Anna Ljung, CEO of Moberg Pharma AB.

CONTACT:

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: [email protected]

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 a.m. CET on December 23, 2021.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/moberg-pharma/r/the-medical-products-agency-in-sweden-will-be-reference-member-state-for-moberg-pharma-s-european-re,c3477705

The following files are available for download:

https://mb.cision.com/Main/1662/3477705/1514041.pdf

The Medical Products Agency in Sweden will be reference member state for Moberg Pharmaâ?tms European registration application

 

SOURCE Moberg Pharma


These press releases may also interest you

at 13:27
Local Dermatologist from Tareen Dermatology Has Message to Parents About Checking the Safety of Their Teens' Acne Products
In a recent study by Valisure LLC, alarming levels of benzene were found in benzoyl peroxide products commonly used to treat acne in teenagers. Benzene, a known carcinogen, poses serious health risks when exposed to high levels. The Valisure study...

at 13:23
5 Ways Heart Health Care Can Improve
(Family Features) Before the advent of antibiotics, infectious diseases, such as pneumonia, tuberculosis and diphtheria, were the most common causes of death in the industrialized world. Today, heart disease is the leading cause of death in the...

at 13:23
How to Support Your Pet's Health During Summer
(Family Features) As a pet parent, you know your pet's needs are continually evolving. That's true during different stages of growth and even as the seasons change....

at 13:19
SHATTERPROOF AND ANTHEM BLUE CROSS AND BLUE SHIELD FOUNDATION PARTNER TO REDUCE HEALTHCARE STIGMA AROUND SUBSTANCE USE DISORDER
A substance use disorder (SUD) is a complex and often stigmatized health condition that affects countless individuals, families and communities. Stigma against people with a SUD extends beyond individual and interpersonal levels. The Shatterproof...

at 12:59
Myasthenia Gravis Foundation of America (MGFA) Kicks off Annual National MG Patient Conference With Program Announcements
More than 400 members of the myasthenia gravis (MG) rare disease community will come together this week at the MGFA National Patient Conference for support and a better understanding of how to manage their disease while learning about the latest...

at 12:36
Kedrion Announces Rare Disease Medicine RYPLAZIM® Now Available in US
Kedrion Biopharma Inc., an international biopharmaceutical company specializing in the research and development, production, and commercialization of plasma-derived therapeutic products used in treating rare and serious diseases, announced today that...

More news about Health...


News published on and distributed by: